Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 3, Issue 3, 2000, Pages 191-195

  Hommes, Daan W ^a   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; IMMUNOREGULATION; MUCOSA INFLAMMATION; PATHOGENESIS; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE;

CROHN DISEASE; CYTOKINES; HUMANS; INTESTINAL MUCOSA; T-LYMPHOCYTES;

EID: 0033928724     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200005000-00005     Document Type: Review

References (35)

1. Sandler RS. Epidemiology of inflammatory bowel disease. In: Inflammatory bowel disease; from bench to bedside. Targan SR, Shanahan F (editors). Baltimore, Williams & Wilkins; 1994. pp. 5-30.
2. Goligher JC. Surgical treatment of Crohn's disease affecting mainly or entirely the large bowel. World J Surg 1988; 12:186-190.
3. MacDonald TT, Pender SLF. Chemical immunology: mucosal T-cells, vol 71. MacDonald TT (editor). Karger; 1998. pp. 103-107. This is an in-depth review on mucosal T-cells.
4. + T cells through IL-12 produced by Listeria-induced macrophages [see comments]. Science 1993; 260:547-549.
5. + T cells. J Immunol 1995; 154:5071-5079.
6. Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158:1541-1550.
7. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89:6065-6069.
8. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A Cd4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
9. + T cells. J Exp Med 1996; 183:2669-2674.
10. + T cells. Immunity 1994; 1:553-562.
11. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220.
12. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993; 178:2207-2211.
13. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-924.
14. Willems F, Marchant A, Delville JP, Gérard C, Delvaux A, Velu T, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24:1007-1009.
15. Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997; 7:861-871.
16. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109:1344-1367.
17. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10:387-398.
18. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998; 188:1929-1939.
19. Cahill RJ, Foltz CJ, Fox JG, Dangler CA, Powrie F, Schauer DB. Inflammatory bowel disease: an immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect Immun 1997; 65:3126-3131.
20. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66:5224-5231.
21. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Distribution and density of TNF immunoreactivity in chronic inflammatory bowel disease. Adv Exp Med Biol 1995; 371B:1327-1330.
22. Radema SA, Stronkhorst A, Bijl H, Tytgat GNJ, van Deventer SJH. Anti-CD4 therapy decreases epithelial expression of HLA-DR molecules in patients with Crohn's disease. Inflamm Bowel Dis 1995; 1:193-197.
23. Camoglio L, te Velde AA, Tigges AJ, Das PK, van Deventer SJH. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 1998; 4:285-290.
24. Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Strober W. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999; 116:557-565. This paper provides new insight into T-cell regulation and Crohn's disease.
25. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a bcl-2/Bax mucosal imbalance. J Immunol 1999; 163:1081-1090. Provides new insight into the relationship between Crohn's disease and T-cell regulation.
26. Van Deventer SJH. Immunotherapy of Crohn's disease. Scand J Immunol 2000; 51(1): 18-22.
27. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, van Deventer S. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342:173-174.
28. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
29. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody Ca2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337:1029-1035.
30. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
31. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383-389.
32. Fedorak RN, Gangl A, Elson CO, et al. Safety, tolerance, and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease. In: Digestive disease week abstract book. 1998.
33. van Montfrans C, van de Ende A, Fedorak RN, et al. Anti- and proinflammatory effects of interleukin-10 in mild to moderate Crohn's disease. Gastroenterology 1999; 177:58-64.
34. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58-64.
35. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan Jr WR. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114:1133-1142.